IGF1R and adrenal cortex carcinoma: Moreover, treatment of ACC cells with the IGF1R inhibitors linsitinib or BMS-754807, both known to downregulate MYB-NFIB expression16, also caused a significant decrease in the expression of ATR (Fig. 3g).